At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|November 14, 2022
Dr. Harris discusses staffing and regulatory challenges faced by urologists
Author(s)Urology Times staff
"People are starting to retire, and there isn't that much production of urologists every year; there's about 270 that come out for the whole country," says Richard Harris, MD.
Advertisement
In this interview, Richard Harris, MD, FACS, discusses some of the biggest challenges facing urology practices today, including those with staffing and regulations. Harris is the CEO and President of UroPartners and a practicing urologist in Chicago, Illinois. He was interviewed at the
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
How PSMA-PET shapes staging and recurrence workup in prostate cancer
3
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5